Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi(Université Paris-Sud), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Arturo Molina(Janssen (United States)), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Kim N.(BC Cancer Agency), Robert J. Jones, John Staffurth(Velindre NHS Trust), Scott North, Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Fred Saad(Université de Montréal), Paul N. Mainwaring(Australasia Paediatric Endocrine Group), Stephen Harland(CRUK Lung Cancer Centre of Excellence), Oscar B. Goodman, Cora N. Sternberg(Carlo Forlanini Hospital), Jin Hui Li(Janssen (United States)), Thian Kheoh(Janssen (United States)), Christopher M. Haqq(Janssen (United States)), Johann S. de Bono
Cited by 1,382
Abstract
Related Papers
No related papers found
Powered by citation graph analysis